6 results on '"Khairy, Dina Ahmed"'
Search Results
2. EBV promotes tumorigenicity and worsens the prognosis of Hodgkin lymphoma through the expression of survival enhancing proteins by activating the JAK / STAT and NF-kB signaling pathways. (A comparative study between EBV positive and negative Hodgkin lymphoma)
- Author
-
Alabiad, Mohamed Ali, primary, Balata, Rawda, additional, A, Mahmoud Asmaa, additional, Metwally, Elsayed Anany, additional, Shalaby, Amany, additional, Samy, Walaa, additional, Yehia, Ahmed M M., additional, Said, Warda M. M., additional, Khairy, Dina Ahmed, additional, Yahia, Amar Ibrahim Omar, additional, and Abdelrahman, Doaa, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Evaluation of Some Prognostic Biomarkers in Human Papillomavirus-Related Multiphenotypic Sinonasal Carcinoma.
- Author
-
Alabiad, Mohamed Ali, Said, Warda M. M., Adim, Amal M. A., Alorini, Mohammed, Shalaby, Amany Mohamed, Samy, Walaa, Elshorbagy, Shereen, Mandour, Doaa, Saber, Ibrahim Mohamed, Yahia, Amar Ibrahim Omar, and Khairy, Dina Ahmed
- Subjects
- *
CANCER prognosis , *ONCOLOGIC surgery , *PAPILLOMAVIRUS diseases , *PARANASAL sinus cancer , *VASCULAR endothelial growth factors , *PROTEINS , *LYMPH nodes , *TELOMERASE , *CANCER relapse , *SYMPTOMS , *CHI-squared test , *AGE distribution , *DESCRIPTIVE statistics , *IMMUNOHISTOCHEMISTRY , *KAPLAN-Meier estimator , *METASTASIS , *REVERSE transcriptase inhibitors , *SURVIVAL analysis (Biometry) , *TUMOR classification , *PROGRESSION-free survival , *BIOMARKERS , *PHENOTYPES , *EPIDERMAL growth factor receptors , *NUCLEAR factor E2 related factor , *OVERALL survival , *DISEASE complications - Abstract
Background: Human papillomavirus (HPV)-related multi phenotypic sinonasal carcinoma (HMSC) is a recently described tumor subtype with an unknown prognosis, often misdiagnosed with other sinonasal carcinomas, and associated with highrisk HPV (HR-HPV). The present study aimed to evaluate the expression of vascular endothelial growth factor (VEGF), Bcl-2-associated X protein (BAX), epidermal growth factor receptors (EGFR), ProEx™C, and human telomerase reverse transcriptase (hTERT) and assess their association with survival and clinicopathological characteristics. Methods: Between 2017 and 2022, 40 HMSC patients underwent surgical resection at the School of Medicine, Zagazig University Hospitals (Zagazig, Egypt). Tissue samples were examined for the presence of HR-HPV; absence of myeloblastosis (MYB), MYB proto-oncogene like 1 (MYBL1), and nuclear factor I/B (NFIB) fusions and the presence of myoepithelial proteins (calponin, S100, SMA), squamous differentiation markers (p63, p40, calponin), VEGF, BAX, ProEx™C, and hTERT by immunohistochemistry. All patients were followed up for about 54 months until death or the last known survival data. Data were analyzed using the Chi square test and Kaplan-Meier method. Results: The expression of VEGF, hTERT, and ProEx™C was significantly associated with age, advanced tumor stages, lymph node metastasis, tumor size, mortality, relapse, poor disease-free survival (DFS), and overall survival (OS) (P<0.001). BAX expression was significantly associated with tumor size, age, poor DFS, and relapse (P=0.01, P<0.001, P=0.035, and P=0.002, respectively). Conclusion: HMSC is strongly associated with HR-HPV. The expression of VEGF, EGFR, BAX, hTERT, and ProEx™C is associated with aggressive malignant behavior, poor survival, and poor prognosis, making them novel prognostic biomarkers for targeted therapeutics in HMSC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Effect of Aromatase Inhibitor Letrozole on the Placenta of Adult Albino Rats: A Histopathological, Immunohistochemical, and Biochemical Study.
- Author
-
Alabiad, Mohamed Ali, Elhasadi, Ibtesam, Alnasser, Sulaiman Mohammed, Alorini, Mohammed, Alshaikh, Ahmed Baker A., Jaber, Fatima A., Shalaby, Amany Mohamed, Samy, Walaa, Heraiz, Ahmed Ismail, Mohammed Albakoush, Khalid Mohammed, and Khairy, Dina Ahmed
- Subjects
- *
STATISTICS , *LETROZOLE , *ANIMAL experimentation , *ONE-way analysis of variance , *APOPTOSIS , *TREATMENT effectiveness , *RATS , *COMPARATIVE studies , *ESTROGEN receptors , *AROMATASE inhibitors , *PLACENTA , *CHI-squared test , *ECTOPIC pregnancy , *DATA analysis , *VASCULAR endothelial growth factors , *PROGESTERONE receptors , *EXTRACELLULAR vesicles , *PHARMACODYNAMICS , *BLOOD - Abstract
Background: Letrozole, an aromatase inhibitor, has recently been introduced as the preferred treatment option for ectopic pregnancy. To date, no study has investigated the effect of letrozole alone on placental tissue. The present study aimed to evaluate the effect of different doses of letrozole on the placenta of rats and to clarify the underlying mechanism. Methods: Sixty pregnant female rats were equally divided into three groups, namely the control group (GI), low-dose (0.5 mg/Kg/day) letrozole group (GII), which is equivalent to the human daily dose (HED) of 5 mg, and high-dose (1 mg/Kg/day) letrozole group (GIII), equivalent to the HED of 10 mg. Letrozole was administered by oral gavage daily from day 6 to 16 of gestation. Data were analyzed using a one-way analysis of variance followed by Tukey's post hoc test and Chi square test. P<0.05 was considered statistically significant. Results: Compared to the GI and GII groups, high-dose letrozole significantly increased embryonic mortality with a high postimplantation loss rate (P<0.001) and significantly reduced the number of viable fetuses (P<0.001) and placental weight (P<0.001) of pregnant rats. Moreover, it significantly reduced placental estrogen receptor (ER) and progesterone receptor (PR) (P<0.001) and the expression of vascular endothelial growth factor (P<0.001), while increasing the apoptotic index of cleaved caspase-3 (P<0.001). Conclusion: Letrozole inhibited the expression of ER and PR in rat placenta. It interrupted stimulatory vascular signals causing significant apoptosis and placental vascular dysfunction. Letrozole in an equivalent human daily dose of 10 mg caused a high post-implantation loss rate without imposing severe side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The prognostic Value of Cancer Stem Cell Marker, Cluster of Differentiation 133 Expression in Stage III Colorectal Carcinoma.
- Author
-
Alabiad, Mohamed Ali, Said, Warda M. M., Elhasadi, Ibtesam, Shalaby, Amany Mohamed, Alorini, Mohammed, Elfarargy, Ola M., Taha, Heba F., Yehia, Ahmed M., Khairy, Dina Ahmed, and Mahmoud, Abla Sayed
- Subjects
- *
COLORECTAL cancer , *CANCER stem cells , *PROGNOSIS , *DISEASE relapse , *RECTAL cancer , *LYMPHATIC metastasis - Abstract
Background: Colorectal cancer (CRC) is the 3rd most prevalent diagnosed cancer and the 4th leading cause of cancer-related deaths globally. Nodal staging is significantly more essential in rectal cancer that detects most the therapy options. Objectives: This study aimed to evaluate CD133 expression in the colorectal carcinoma stage III using immunohistochemistry as well as its relationship to clinicopathological characteristics and patient outcomes. Patients and Methods: The study includes 60 cases with stage III CRC five years after surgical removal of the tumor and regular follow-up with the Departments of Medical and Clinical Oncology where clinicopathological and prognostic data are collected from the archives. The patients were classified into two groups, GI includes 22 CRC patients with relapse, and GII includes 38 CRC patients without relapse. Sixty archive paraffin blocks of primary resection and metastatic lymph nodes were extracted from the archives of the Pathology Department processed for CD133 immunohistochemistry. CD133 expression levels were assessed, analyzed, and correlated with clinicopathological and prognostic criteria. Results: Positive CD133 expression was significantly linked with old age (P=0.034), large tumor size (p < 0.001), perineural invasion (p = 0.0017), lympho-vascular invasion (P < 0.001), high-grade (p < 0.001), resistance to chemotherapy (p = 0.011), lymph nodes metastasis and relapse (p = 0.005*) and DFS (p = 0.005). Conclusion: CD133 expression in colorectal carcinoma is related to tumour progression and is considered a marker of poor prognosis and a strong indicator of relapse and poor survival. Moreover, CD133 stem cell marker may act as a targeted therapy in chemotherapeutic resistance patients with colorectal carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Moesin and Ezrin as New Promising Markers for Early Detection of Endometrial Carcinoma: An Immunohistochemical Study.
- Author
-
Salama MEM and Khairy DA
- Subjects
- Humans, Female, Hyperplasia, Early Detection of Cancer, Endometrial Neoplasms diagnosis
- Abstract
Objective: the aim of this study is to evaluate immunohistochemically the expression of ezrin, and moesin, in endometrial lesion cases in order to detect EC at early stages which will have an important implication on the patients' outcome., Method: 100 stored, formalin-fixed, paraffin-embedded tissue blocks of endometrial curettage obtained due to abnormal uterine bleeding or postmenopausal bleeding were collected. Each paraffin block was re-cut by rotatory microtome at 4 μm thickness then mounted on a glass slide and stained by hematoxylin and eosin for routine histopathological examination and on charged slides for immunohistochemistry using an automated staining system (Dako autostainer link 48) with antibodies against Moesin and Ezrin. Cytoplasmic staining was evaluated for both Moesin and Ezrin based on the intensity and extent of staining and scored for each sample., Result: Both Moesin and Ezrin were significantly higher in atypical endometrial hyperplasia compared to benign hyperplasia and significantly higher in endometrial carcinoma compared to atypical hyperplasia. Moesin also significantly correlated with higher tumor grades while Ezrin was significantly higher in postmenopausal women denoting their role in tumor progression and poor prognosis., Conclusion: Both Moesin and Ezrin could be potentially used as predictive markers for endometrial carcinoma screening programmes as well as indicators for cancer progression.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.